Skip to main content

Advocacy

IASLC
How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research AdvocacyResearchTreatments

How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research

*August 2021* It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global…
laurabbook@gmail.com
November 10, 2021
New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF) AdvocacyFundingPartners

New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF)

*June 2021* The EGFR Resisters is thrilled to announce a new multi-year research partnership with Lung Cancer Research Foundation (LCRF)!  LCRF is a large non-profit lung cancer advocacy organization based in New York whose mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and…
cece
June 24, 2021
lungevity
LUNGevity’s HOPE Summit: Ivy Elkin’s Journey to Research Advocacy AdvocacyStories

LUNGevity’s HOPE Summit: Ivy Elkin’s Journey to Research Advocacy

*May 2021* EGFR Resister co-founder Ivy Elkins  presented with Dr. Upal Basu Roy, Executive Director of LUNGevity, on “Understanding the Science of Lung Cancer and Research Advocacy” at the 2021 Hope Summit on Saturday, May 22. Her portion of the presentation centered on the importance of patient-driven research and her…
cece
June 21, 2021
Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions Advocacy

Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions

*January 2021* Jill Feldman, co-founder of the EGFR Resisters, presented on Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions to help ensure every decision, starting at concept is looked at through a health equity lens. Creating clinical trials WITH us not just FOR us! It is a moral imperative…
laurabbook@gmail.com
March 6, 2021
Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer Advocacy

Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer

*November 2020* Communities sharing particular types of the disease are helping steer research towards better therapies. Patient advocates often want immediate results but this can be at odds with the slow pace of scientific investigation. Yet clinicians and scientists who have collaborated with advocacy groups say they are an invaluable…
laurabbook@gmail.com
January 6, 2021
EGFR Resisters logo
Project PRIORITY: Why it matters to the EGFR-positive lung cancer community AdvocacyCoping With CancerResearch

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project PRIORITY To understand unmet needs of the EGFR-positive lung cancer…
laurabbook@gmail.com
December 20, 2019
EGFR Resisters logo
Learnings from EGFR Resisters’ Project Priority at IASLC 2019 AdvocacyCoping With Cancer

Learnings from EGFR Resisters’ Project Priority at IASLC 2019

*October 2019*  Presented by EGFR Resisters Co-Founders. * Hospitalization - While TKIs are superior to other treatments for EGFR positive lung cancer patients, there is still a large number that experience severe side effects that require urgent medical care and/or hospitalization. * Mental health - it only represents depression diagnosed…
laurabbook@gmail.com
November 8, 2019